Maria C Freire has sold stock and made no open-market buys since May 2017

Maria C. Freire, Ph.D.

Maria C. Freire, Ph.D., has served as an independent director on the board of Exelixis, Inc. (NASDAQ: EXEL) since April 2018.( On May 7, 2026, she sold common stock totaling $949,164.( She is also a director at Biogen Inc. since June 2021, where she serves on the Compensation and Management Development Committee and Corporate Governance Committee,( and at Alexandria Real Estate Equities, Inc. since April 2012, Koneksa Health since July 2022, and Keystone Symposia on Molecular and Cell Biology.( Dr. Freire is the Founder and Principal of The Freire Group, a strategic advisory firm for life sciences organizations.(

Her career highlights include serving as President and Executive Director of the Foundation for the National Institutes of Health (2012–2021), President of the Albert and Mary Lasker Foundation (2008–2012), President and CEO of the Global Alliance for TB Drug Development (2001–2008), and Director of the Office of Technology Transfer at the National Institutes of Health (1995–2001).( She is a member of the National Academy of Medicine and the Council on Foreign Relations, and has received awards such as the 2017 Gold Stevie Award for “Woman of the Year” and the U.S. Department of Health and Human Services Secretary’s Award for Distinguished Service.( Dr. Freire holds a Ph.D. in Biophysics from the University of Virginia and a B.S. from the Universidad Peruana Cayetano Heredia in Lima, Peru.(

Written by Perplexity from public sources.